Clinical Trials Logo

BRCA1 Gene Mutation clinical trials

View clinical trials related to BRCA1 Gene Mutation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03377556 Completed - BRCA1 Gene Mutation Clinical Trials

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Start date: March 3, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02197000 Completed - BRCA2 Gene Mutation Clinical Trials

A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers

Start date: November 11, 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether adding DIM supplement will decrease breast density among female BRCA mutation carriers in two years.

NCT ID: NCT01975363 Completed - Clinical trials for Ductal Breast Carcinoma in Situ

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

Start date: June 2013
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies a nanoemulsion formulation of curcumin in reducing inflammatory changes in breast tissue in obese women at high risk for breast cancer. Curcumin may reduce inflammation in breast tissue and fat. This may affect the risk of developing breast cancer.

NCT ID: NCT01948609 Completed - BRCA2 Gene Mutation Clinical Trials

Prospective Research of Outcomes After Salpingo-oophorectomy

PROSper
Start date: July 2014
Phase:
Study type: Observational

PROSper is a prospective cohort study of 100 women 35-50 years of age with BRCA 1/2 mutations who have elected to either undergo risk reducing salpingo-oophorectomy (RRSO) or nonsurgical management. The investigators will compare the change in cardiovascular health, bone health, sexual function, quality of life, and menopausal symptoms over 3 years of follow-up between women who undergo RRSO (baseline just prior to surgery) and age-matched controls that do not undergo RRSO. The investigators hypothesis is that women who undergo a premature surgical menopause induced by RRSO have worse cardiovascular health and bone health compared with women who do not undergo RRSO.

NCT ID: NCT01251874 Completed - Clinical trials for Recurrent Breast Carcinoma

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Start date: November 16, 2010
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of veliparib when given together with carboplatin and to see how well they work in treating patients with human epidermal growth factor 2 (HER2)-negative breast cancer that has spread to other parts of the body. Carboplatin kills cancer cells by damaging the deoxyribonucleic acid (DNA) that lets the cancer cell survive and reproduce. The body has proteins that try to repair the damaged DNA. Veliparib may prevent these proteins from repairing the DNA so that carboplatin may be able to kill more tumor cells. Giving veliparib with carboplatin may kill more tumor cells than carboplatin alone.